Similarly, in a model with concurrent subcutaneous and intracranial EMT6 breast carcinoma tumors, rejection of s.c. tumors through peri-tumoral administration of CpG ODN potentiated the infiltration of CD4+, CD8+ T cells and NK cells into established intracranial tumors (Xiong et al., 2008). The gene discussed is CD4; the disease is breast carcinoma.